Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MWN117 is an investigational small interfering RNA (siRNA) therapeutic designed to target inhibin subunit beta E (INHBE) for the treatment of overweight and obesity. Developed by Shanghai Minwei Biotechnology, a subsidiary of Lepu Medical, MWN117 downregulates INHBE gene expression in hepatocytes. INHBE is associated with inhibiting lipolysis, promoting fat storage, and inducing insulin resistance. By silencing this target, MWN117 promotes lipolysis and reduces lipid accumulation. In preclinical models, MWN117 has demonstrated the ability to significantly reduce body fat percentage and visceral fat while simultaneously increasing muscle mass, offering a potential muscle-sparing profile for weight management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MWN117.